Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...
As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva in ...
The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation. The ...
With GSK’s consumer healthcare spinoff now in the rearview mirror, the company is operating as the lean, innovative medicines-focused drugmaker CEO Emma Walmsley envisioned years ago (PDF). And 2022’s ...
Johnson & Johnson JNJ announced that the FDA has approved its long-acting injectable HIV regimen, Cabenuva, for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 ...
Evergreen Health has begun using Cabenuva (Cabotegravir and Rilpivirine), an HIV-1 treatment regimen approved by the U.S. Food and Drug Administration in January and trialed by Evergreen’s own ...
Initiating treatment may become easier for adults living with HIV. The US Food and Drug Administration has approved a label update that allows adults living with HIV to begin treatment with Cabenuva ...
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...
ViiV Healthcare has received the Food and Drug Administration's permission for Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less ...
U.S. regulators have approved the first long-acting drug combo for HIV, monthly shots that can replace the daily pills now used to control infection with the AIDS virus. Thursday’s approval of the two ...
Following the release of positive results for Phase III trial of ViiV Healthcare and GSK’s long-acting injectable antiretroviral treatment (ART) Cabenuva (cabotegravir + rilpivirine); Barbora Salcman, ...
A new monthly HIV treatment — the first of its kind — could benefit hundreds of thousands of people currently taking daily pills to prevent the virus from leading to AIDS. ViiV Healthcare, a Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results